Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine versus brimonidine for prevention of intraocular pressure elevation after Nd:YAG laser capsulotomy
IRCT20231008059648N1Phase 3Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in posterior capsule opacification (PCO) comparing Dexmedetomidine 0.008% group with Brimonidine 0.2% group (2 arms). Primary endpoints: Intraocular pressure, Nausea and 7 more. Started Jan 2024; status: completed.
02
Drugs
dexmedetomidinebrimonidine
03
Conditions
posterior capsule opacification (PCO)
Beyond the preview
Go deeper on IRCT20231008059648N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20231008059648N1.